Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

22 Trials of atacicept, which blocks the activity of two B-cell survival factors, BAFF and APRIL were terminated prematurely in phase II/III due to safety concerns; however, the data showed a trend to benefit for the higher dose tested. 23 Studies of B cell-directed agents continue, with modifications to improve efficacy, such as obinutuzumab, an anti-CD20 mAb engineered for enhanced cytotoxicity ( NCT02550652 ).
tujafilina population analyzed in the present study, a statistical analysis of the absolute copy numbers of gro EL and atp D revealed that although both endosymbiotic bacteria showed a trend line with a positive slope (0.0540 for B. aphidicola BCt; 0.0296 for S. symbiotica SCt; Fig. 4B ), a significant positive correlation was only observed between the average temperature recorded and the amount of B. aphidicola BCt ( p =0.002).
44,45 Overexpression of WAVE1-A and WAVE1-B (but not WAVE1-C) showed a trend toward increasing the expression of embryonic genes, while knockdown of WAVE1 in embryos through MO-injections caused a downregulation of many genes, including hox genes, indicating that nuclear WAVE1 plays a role in embryonic development ( Fig. 2G ). 45 Co-immunoprecipitation experiments with nuclear extracts of an NLS-WAVE1–A or –B fusion protein were conducted to identify nuclear WAVE1 interactors.
Moreover, unlike the previous study that showed a trend in favor of doublet agents with respect to OS, but the difference was not statistically significant partly due to the limited RCTs included, we demonstrated for the first time that doublet agents were more efficacious in terms of OS (HR 0.90, 95% CI 0.84–0.96, P =0.002), PFS (HR 0.81, 95% CI 0.76–0.88, P <0.001), and ORR (RR 1.72, 95% CI 1.34–2.21, P <0.001) when compared with single-agent therapy ( Figure 2A and B ) in the anthracyline- and taxane-pretreated breast cancer patients.
13 Multivariate analysis adjusted for sex, stage, type of surgery, and adjuvant chemotherapy showed a trend toward a higher 2-year survival rate in the 56 patients (33%) who received a TKI perioperatively (96% vs 90%), but no firm conclusion can be drawn in the absence of randomization. 13 An open, randomized, Phase II trial conducted in Asia, after surgery and adjuvant chemotherapy (four cycles of pemetrexed–carboplatin), compared a 6-month course of gefinib with simple monitoring in EGFR-mutated, stage IIIA-N2 NSCLC patients.